SEC Form 4 · accession 0001179110-17-006715
ENDOCYTE INC · ECYT
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
John C Aplin
Director
Period of report
May 4, 2017
Accepted (ET)
May 5, 2017 · 5:09 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001235007
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | May 4, 2017 | A | 3,300 | $0.00 | A | 28,863 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (right to buy)F2 | $2.27 | May 4, 2017 | A | 19,500 | A | — | May 4, 2027 | Common Stock | 19,500 | 19,500 | D |
Explanation of responses
- F1Represents restricted stock units that will vest 100% on the business day prior to the next annual stockholder meeting following the date of grant, and will be paid in the form of one share of common stock for each restricted stock unit.
- F2100% of options vest on the business day prior to the next annual stockholder meeting following the date of grant.